-+ 0.00%
-+ 0.00%
-+ 0.00%

Evommune Presents EVO301 Phase 2a Data Showing Primary Endpoint Met in Atopic Dermatitis

PUBT·11/12/2026 21:15:43
Listen to the news
Evommune Presents EVO301 Phase 2a Data Showing Primary Endpoint Met in Atopic Dermatitis
  • Evommune’s EVO301 met its Phase 2a atopic dermatitis primary endpoint, delivering 33% placebo-adjusted EASI improvement at week 12.
  • No treatment-related serious or severe adverse events occurred; no conjunctivitis was reported.
  • Phase 2b initiation in atopic dermatitis is planned for mid-2027; Phase 2a initiation in ulcerative colitis is targeted for first-half 2027.
  • EVO756 Phase 2b migraine trial top-line data are expected in the second half of 2027.
  • Approximately $290 million in cash and investments provides a projected runway into the second half of 2029.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Evommune Inc. published the original content used to generate this news brief on November 12, 2026, and is solely responsible for the information contained therein.